Shire Patent Suit Over Generic Intuniv Survives

Law360, New York (August 29, 2011, 7:38 PM EDT) -- A California federal judge on Monday denied Impax Laboratories Inc. and Watson Pharmaceuticals Inc.'s attempt to dismiss a patent infringement suit brought by Irish drugmaker Shire PLC over a generic version of its attention deficit hyperactivity disorder drug Intuniv.

When Shire moved to strike all of Impax and Watson's counterclaims and affirmative defenses in February for failure to state a claim, the defendants countered with a motion to dismiss the suit, saying their answers to Shire's complaint are pleaded in the same fashion as the complaint...
To view the full article, register now.